secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001213900-24-042966
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma Q2 net loss $8.5M; LYMPHIR PDUFA Aug 13, Mino-Lok data due Q2
---------------------------------------------------------------------------

- Cash $12.6M at Mar 31; $15M April offering extends runway through Dec 2024.
- LYMPHIR BLA accepted with PDUFA target date August 13, 2024.
- Mino-Lok Phase 3 topline results anticipated in calendar Q2 2024.
- Merger of oncology sub with TenX (TENK) progressing; pending SEC/TENK approval.
- Net loss $8.5M ($0.05/shr) vs $10.5M loss a year ago; R&D expense down.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024042966/0001213900-24-042966-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024042966/ea0206086-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-042966

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer